PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
Authors
Keywords
BRAF, Melanoma, Colorectal cancer, Paradoxical activation, MAPK pathway
Journal
Molecular Cancer
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-28
DOI
10.1186/s12943-017-0684-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
- (2015) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma
- (2015) Matteo S. Carlino et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
- (2014) D. Mouradov et al. CANCER RESEARCH
- Progression ofKRASmutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma
- (2014) A. Grey et al. INTERNAL MEDICINE JOURNAL
- Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors
- (2014) Kevin J. Basile et al. Pigment Cell & Melanoma Research
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
- (2013) Miles C. Andrews et al. JOURNAL OF CLINICAL ONCOLOGY
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
- (2013) Geoffrey T. Gibney et al. Nature Reviews Clinical Oncology
- Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
- (2013) Jaehyuk Choi et al. Pigment Cell & Melanoma Research
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now